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Abstract
Background: The bacterium Corynebacterium pseudotuberculosis (Cp) causes caseous lymphadenitis (CLA),
mastitis, ulcerative lymphangitis, and oedema in a number of hosts, comprising ruminants, thereby intimidating
economic and dairy industries worldwide. So far there is no effective drug or vaccine available against Cp.
Previously, a pan-genomic analysis was performed for both biovar equi and biovar ovis and a Pathogenicity
Islands (PAIS) analysis within the strains highlighted a large set of proteins that could be relevant therapeutic
targets for controlling the onset of CLA. In the present work, a structural druggability analysis pipeline was
accomplished along 15 previously sequenced Cp strains from both biovar equi and biovar ovis.
Methods and results: We computed the whole modelome of a reference strain Cp1002 (NCBI Accession:
NC_017300.1) and then the homology models of proteins, of 14 different Cp strains, with high identity (≥ 85%)
to the reference strain were also done. Druggability score of all proteins pockets was calculated and only those
targets that have a highly druggable (HD) pocket in all strains were kept, a set of 58 proteins. Finally, this
information was merged with the previous PAIS analysis giving two possible highly relevant targets to conduct
drug discovery projects. Also, off-targeting information against host organisms, including Homo sapiens and a
further analysis for protein essentiality provided a final set of 31 druggable, essential and non-host homologous
targets, tabulated in table S4, additional file 1. Out of 31 globally druggable targets, 9 targets have already
been reported in other pathogenic microorganisms, 3 of them (3-isopropylmalate dehydratase small subunit,
50S ribosomal protein L30, Chromosomal replication initiator protein DnaA) in C. pseudotuberculosis.
Conclusion: Overall we provide valuable information of possible targets against C. pseudotuberculosis where some
of these targets have already been reported in other microorganisms for drug discovery projects, also discarding
targets that might be physiologically relevant but are not amenable for drug binding. We propose that the
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constructed in silico dataset might serve as a guidance for the scientific community to have a better understanding
while selecting putative therapeutic protein candidates as druggable ones as effective measures against C.
pseudotuberculosis.
Background
Efforts to find new bacterial drug and/or vaccine targets
are becoming indispensable due to the antimicrobial
resistance, rapid loss of effectiveness in antibiotic treat-
ment and the quantitative emergence of multi-resistant
microbial strains that pose a global challenge and threat.
Corynebacterium pseudotuberculosis (Cp) is a pathogen
of great veterinary and economic importance, since it
affects a broad spectrum of animal livestock worldwide,
mainly sheep and goats, as well as mammals in numerous
Asiatic, Arabic and African countries, North and Latin
America and Australia [1]. C. pseudotuberculosis is a
Gram-positive, facultative intracellular and pleomorphic
organism; it possesses fimbriae but is non-motile in nat-
ure [2]. The rpoB gene analysis for CMNR group of
bacteria (Corynebacterium, Mycobacterium, Nocardia
and Rhodococcus), which has a great medical, veterinary
and biotechnological importance, has shown a close phy-
logenetic relationship [3]. A number of pathogenic
strains from a wide range of hosts have already been
sequenced, demonstrating the importance of this micro-
organism [3]. The pathogen infects goat and sheep popu-
lations (biovar ovis), causing caseous lymphadenitis
(CLA), a chronic contagious disease with abscess forma-
tion in superficial lymph nodes and subcutaneous tissues.
Biovar equi, on the other hand, infects lung, kidney, liver
and spleen in higher mammals like cow, camel, buffalo
etc. thereby, threatening the life of herd animals [2,4].
There are few reports in humans of symptoms similar to
lymphadenitis abscesses, caused by an occupational expo-
sure to the infected animals [5-7]. Bearing in mind the
medical importance of C. pseudotuberculosis due to a
lack of efficient medicines, here, we have made an effort
and applied a computational strategy to search for new
therapeutic molecular targets from this bacterium.
Homology modelling is a widely used technique that
has proved good results to expand structural space of
pathogens [8,9]. We have designed and implemented a
protein structure prediction pipeline using homology
modelling based on Martí-Renom methodologies [10].
The pipeline was applied to the randomly selected
Cp1002 genome as a reference strain; the genomes of
other strains were modelled using a mutation procedure,
the sequences that present homology in both, i.e., the
core genome, were already modelled in the reference
strain Cp1002.
The main purpose of this study is to offer information
based on recently reported structure-based prediction of
protein druggability that might be valuable for target
selection in drug design projects. Druggability is a con-
cept used to describe the ability of a given protein to
bind a drug-like molecule, which in turn modulates its
function in a desired way. Purely, from a structural
point of view, it is the likelihood that small drug-like
molecules bind a given target protein with high affinity
(< 1µM), a concept also referred to “bind ability”. Early
attempts to determine the druggable genome of an
organism were based on counting the number of targets
belonging to known druggable domains that have
yielded values in range of 10-14% for the human gen-
ome. According to our knowledge, a structural drugg-
ability assessment for the C. pseudotuberculosis multi-
strain proteome was never performed before.
Recently, we developed a fast method for druggability
prediction based on the open source pocket detection
code “fpocket”, which combines several physicochemical
descriptors to estimate the pocket druggability and that
can be used on a genomic scale [11]. Druggable proteins
should have a pocket with suitable features that enable
binding of a drug-like compound. After computing pro-
teins that remains druggable along the 15 Cp genomes,
58 target candidates were selected.
The Cp genome has been reported to include seven
putative pathogenicity islands (PAIS) [12], which contain
several classical virulence factors, including genes for fim-
brial subunits, adhesion factors, iron uptake and secreted
toxins. Additionally, all of the virulence factors in the
islands have characteristics that indicate the phenomenon
of horizontal gene transfer. The importance of our dataset
is enhanced with the emerged information from the litera-
ture regarding the PAIS, pan-genome and also with the
pan-modelome strategies for target selection [38].
Methods
General concept
The druggability analysis pipeline consisted of the follow-
ing steps (Figure 1). The Open Reading Frame (ORFs)
sequences of C. pseudotuberculosis were obtained from
the GenBank database [13,14]. All ORFs were then ana-
lysed with the HMMer software and the structural
domains were assigned. Then, each ORF was used to per-
form a BLAST search against the Protein Data Bank to
determine which structure(s) will be used as template(s)
to perform homology modelling of the ORFs or com-
puted domains. For all the 3D modelled structures, a set
of structural properties were computed, including: i) the
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Druggability Score (DS) for each pocket, ii) the active site
residues (if available) according to the template struc-
tures, iii) the conserved or family relevant residues. This
information was later combined with the essentiality cri-
teria and the previously related pathogenicity information
present in the literature. A detailed description of the
programs and databases used to perform each of the
above mentioned pipeline step is given below in detail
(Figure 1).
Initial dataset construction
All ORFs or possible proteins for all the strains of Cp
were obtained by downloading the information available
at the NCBI database (ftp://ftp.ncbi.nih.gov/genomes/
Bacteria). The randomly selected strain used as a refer-
ence genome for further calculations is Cp1002, accord-
ing to recent work by Hassan et al., 2014 [38]. The
Cp1002 genome has 2097 reported ORFs.
Pfam domain assignment
All the ORFs in the reference proteome were analysed
with the HMMer program and were later assigned the
Pfam families or domains, leading to a total of 2455
domains assignments from Pfam-A entries and 509 ORFs
with no domain assigned. However, as expected, more
than one ORF can be assigned to the same domain.
Thus, considering this information, a total of 1327
unique (i.e. different) domains were assigned to a whole
Cp reference genome. On average, the Cp reference
genome has 1.87 domains per ORF and 1.58 unique
domains per ORF.
Generation of structural homology-based models
The strain Cp1002 was used a basis for the structural
study. For each sequence in this strain, several models
were built using the following procedures: First, a PSI-
Blast [15] search was performed against UniRef50, using
3 iterations and an e.value threshold of 0.0001, in order
to compute a checkpoint that will be used as a profile for
the target sequence. Second, PSI-Blast search is restarted
using the aforementioned checkpoint against a template
library. The template library consisted of all sequences
from every individual protein chain in the Protein Data
Bank (PDB), grouped at 95% sequence identity threshold
using CD-HIT [16]. Afterward, the target-template align-
ments were computed in the last step, with an e-value
of ≤ 0.00001 to build the model structures using the
MODELLER software [17,18]. For each target-template
alignment, ten different target models were built, and
their quality measures were assessed using the GA341
[19,20] and QMEAN methods [21]. Only the models
with GA341 score ≥ 0.7 (score for the reliability of a
model derived from statistical potentials) [22], were
retained. A reliable model has a probability of correct
fold larger than 95% and coverage of over 50%. Every
sequence belonging to the other 14 strains were com-
pared to strain Cp1002 using BLASTp. For each
sequence that gives a hit with sequence identity above
Figure 1 A general sketch of the pipeline. All outputs, steps and summaries are available for download purpose and later analyses; links are
available in supplementary material.
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85%, a mutation methodology was applied on each amino
acid substitution using MODELLER between this
sequence and the sequence belonging to Cp1002.
Structural assessment of druggability
Structural druggability of each modelled and potential
target was assessed by determining and characterizing
the ability of putative pockets to bind a drug-like mole-
cule by using the fpocket program and the recently
developed Drug Score (DS) [23]. Briefly, the method is
based upon Voronoi Tessellation algorithm to identify
pockets and computes suitable physicochemical descrip-
tors (polar and apolar surface area, hydrophobic density,
hydrophobic and polarity score) that are combined to
yield the DS, which ranges between 0 (non-druggable,
ND) to 1 (highly druggable, HD). In this work we sepa-
rated the druggability score in four sets: non-druggable
proteins (ND; DS ≤ 0.2), poorly druggable (PD; 0.2 < DS
≤ 0.5), druggable (D; 0.5 < DS ≤ 0.7), and highly drug-
gable (HD; DS ≥ 0.7). This distribution based on our
previous study where we computed the druggability
score for all pockets present in all unique proteins in
the PDB, which were crystallized in complex with a
drug-like compound [11]. In Figure 2, we compare the
druggability distribution of all structures of Cp genome
built in this work. Although the distribution has a small
shift to higher values; we use the same bounds to define
the sets of druggable proteins (Figure 2).
Extending this information along the different strains,
those structures labelled as HD in the reference strain
were analysed in the other ones. A protein target, which
remained druggable in all the strains, was classified as
Globally Druggable (GD), also, a protein druggable in all
the virulent strains is classified as Virulent Druggable
(VD). The GD, obviously, remained a subset of VD.
Active site identification
In order to identify the active site pocket, our pipeline
implements two different analyses that rely on; i) the
information from the CSA, and ii) a Pfam position site,
as the importance criteria.
The data from CSA was downloaded from http://
www.ebi.ac.uk/thornton-srv/databases/CSA/ that con-
sisted of a list of PDB_IDs linked to a number of resi-
dues, which comprised the corresponding protein active
site. To map the active site residues to as many Cp pro-
tein domains as possible, each PDB_ID used as a tem-
plate for the homology modelling in CSA was assigned
to the modelled ORFs.
As an alternative approach to determine the relevance
of a given pocket (or residues), we looked for residues
of a given Pfam family/domain that were located in an
important position and are well conserved. Important
positions were defined as those positions in the corre-
sponding HMMer model whose information content
was larger than a defined importance cut-off value
(icov). The nature of the conserved amino acids in the
corresponding position was determined by comparing
each residue type emission probability (ep) with icov. If
the ratio between ep and icov was larger than a con-
served type cut-off value (ctcov), the corresponding resi-
due type was assumed as conserved. Optimal values of
icov and ctcov [11] were 0.27 and 0.24, respectively.
These values were calculated as the ones that allowed
labelling all the important residues of the CSA database
in their respective protein’s domains. Briefly, this
approach is a strategy to extend the definition of cataly-
tic site capturing all the sites described in CSA. CSA is
a curated database with limited amount of data. Our
strategy gives us a clue about new candidates of being
catalytic sites, with some false positives.
By using these analyses, for each Pfam domain, the
pipeline provided a list of position-residue type relevant
residues, which could thus be mapped to all Cp ORFs
with assigned Pfam domain.
Pathogenicity islands and pan-modelomics information
Information collected from other software pipelines is
used in the present work to enhance the target selection
process.
Figure 2 Histogram of druggability score (DS). All ligand-bound
structures in the PDB (blue pointed line) and all the modeled
structures of the C. pseudotuberculosis genome (red line) are
represented in the histogram. The scores were computed using the
fpocket program for all pockets present in all unique proteins in the
PDB, which were crystallized in complex with a drug-like
compound. A Gaussian fit of the data made to define these sets
was performed in Radusky et al., 2014 [11]. The sets are: non-
druggable proteins (ND; DS ≤ 0.2), poorly druggable (PD; 0.2 < DS
≤ 0.5), druggable (D; 0.5 < DS ≤ 0.7), and highly druggable (HD; DS
≥ 0.7). The red line is the distribution of DS over all the models
built in this work.
Radusky et al. BMC Genomics 2015, 16(Suppl 5):S9
www.biomedcentral.com/1471-2164/16/S5/S9
Page 4 of 8
All the ORFs that belonged to a pathogenicity island
(PAIS) were properly labelled with this indicator. The
PAIS were previously computed and identified using the
PIPS software [24] that has predicted 16 pathogenicity
islands in C. pseudotuberculosis. PIPS predicts patho-
genicity islands by taking into account some important
features, i.e., flanking tRNA, codon usage bias, GC con-
tent deviation; transposases, virulence factors and their
absence in non-pathogenic organism of the same genus
or related species. Pathogenicity islands are large regions
that were acquired through horizontal gene transfer that
represent the genome plasticity of a species and possess
a high concentration of virulence factors. Virulence fac-
tors are proteins whose function is related to bacterial
virulence and pathogenicity. They help the pathogenic
bacterium in adhesion mechanisms, invasion, and sur-
viving through colonization, and replication inside the
host as well as in immune system evasion [24].
A novel integrative approach has been adapted in a
recent work for the identification of new therapeutic
targets in C. pseudotuberculosis [38] where a final set of
10 proteins has been selected that was essential for the
bacterial survival. Here, too, a focus was made only on
the previously selected homologous target proteins in
the reference Cp1002 genome, whose detailed analysis
with our pipeline is reported.
Bacterial essential and non-host homologous proteins
analysis
The pool of global highly druggable (GD) 58 target pro-
teins was subjected to NCBI-BLASTp (e-value lesser
than 1e-07, bit score ≥100, identity ≥ 50%) against
human and ovine proteomes to identify non-host homo-
logs targets, and coverage of all the sequences of the pro-
teins greater than 80% [25]. The exhaustive list of GD
and Virulent highly druggable (VD) ORFs is available in
supplementary material table S1, additional file 1.
Furthermore, from the filtered list of 41 highly drug-
gable non-host homologous target proteins, an approach
based on a subtractive genomics was made for the con-
served GD targets that were essential to bacteria [26].
Briefly, the set of proteins from C. pseudotuberculosis
were submitted to the Database of Essential Genes (DEG,
which contains experimentally validated essential genes
from 20 bacteria) for homology analyses [27]. The
BLASTp cut-off values used were: e-value = 1e-05, bit
score ≥100, identity ≥ 35% [26]. The final list of targets
based on previously described criteria contained 31
essential and non-host homologous target proteins. The
list of putative targets was subjected to biochemical path-
way analysis to KEGG (Kyoto Encyclopaedia of Genes
and Genomes) [28], virulence using PIPS (Pathogenicity
Island Prediction Software) [29], functionality using Uni-
Prot (Universal Protein Resource) [30], and cellular
localization using CELLO (subCELlular LOcalization pre-
dictor) [31].
Results and discussion
Models in the reference Cp1002 strain
The following subsections describe the database data
summary after running the HMMer software and the
modelling pipeline.
A total of 2598 models were built from the ORFs of
the reference genome and then a part of the ORFs were
assigned to the Pfam families. Here, 1206 unique ORFs
were involved. The models from the Pfam family were
1546 in total, where only 879 unique Pfam families were
used. The other 1051 models correspond to full ORF
models (table 1).
Models in non-reference strains
The details of these constructed models are presented
here in a tabulated form.
Druggability summary of 15 C. pseudotuberculosis strains
A summary of the calculated structural druggability
scores is presented in table 2. In parentheses are the
pockets containing residues from CSA database or at
least one important residue from the Pfam family,
assigned to the corresponding ORF in the Cp1002 gen-
ome. It should be noted that the pocket calculations
over the non-reference strains were done only for the
homologous models (proteins with identity > 85% to the
reference genome). ORFs with high druggability over all
the strains are labelled as Global druggable and those
druggable in the pathogenic islands as Virulent drug-
gable. For Cp1002 strain, only those ORFs in the list
appear having at least one homolog ORF in another
strain. In other strains, only the ORFs homologous to a
Cp1002 ORF are considered for this table.
Bacterial essential and non-host homologous proteins
analyses
An exhaustive literature review of candidate druggable
targets
As aforementioned, the list of 58 most druggable proteins
(table S1, additional file 1) was compared to the corre-
sponding host proteomes, leading to the identification of
41 non-host homologous proteins (table S2, additional file
1) and 17 host homologous proteins (table S3, additional
file 1). A final list of 31 essential and non-host homolo-
gous targets from C. pseudotuberculosis is given in table
S4, additional file 1 after computing the 41 non-host
homologous proteins to the database of essential genes
(DEG), using the earlier mentioned default parameters.
Based on this filter, the number of selected targets was
drastically reduced to a final set of 31 targets. This list
was considered as druggable, essential and non-host
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homologous target proteins. We have further extrapo-
lated our search to find out whether some of these puta-
tive targets have already been reported in the literature
or not. This way 9 such putative targets were found
where 3 of them including 3-isopropylmalate dehydratase
small subunit, 50S ribosomal protein L30 and Chromoso-
mal replication initiator protein DnaA have previously
been reported in C. pseudotuberculosis [25,26], while the
other 6 druggable target proteins have been reported in
other pathogenic microorganisms, both in bacteria and
parasites (table 3). The remaining 22 druggable targets
that are not yet reported as putative targets were
searched for molecular functions, biological processes,
cellular compartmentalisations and metabolic pathway
roles (table S5, additional file 1).
Conclusions and perspectives
In the present work we have attempted to show a com-
prehensive study of the druggability scores along the
known completely sequenced strains of C. pseudotuber-
culosis species to complement further the research work
performed by our colleagues and collaborators. After
our pipeline was executed, a list of cross-strain highly
druggable 58 ORFs was obtained. These ORFs had the
information about their membership in the set of viru-
lent strains. We too have provided the information if
the most druggable pockets of the ORF have highly con-
served residues in the Pfam families they belong to, and
if a catalytic site is reported in the template structure or
structures that were used to build the homology model
for each ORF. We expect that the constructed dataset
might serve as a guide for the scientific community to
have a better understanding while selecting protein can-
didates as therapeutic and druggable ones. All the data
is available via web at http://www.inquimae.fcen.uba.ar/
turjanski_adrian.
The information obtained here was also used to
exhaustively analyse the target proteins actually consid-
ered as druggable targets in previous works. Our ana-
lyses have proposed a set of putative druggable targets
in the veterinary pathogen C. pseudotuberculosis on one
hand, while on the other hand it has also demonstrated
the efficiency and the high-throughput nature of our
Table 1. Summary of modelling pipeline over non-reference strains
NCBI accession C. pseudotuberculosis strains ORFs Homolog ORFs to Cp1002 Modelled ORFs
NC_017308.1 Cp1/06-A 1963 1654 493
NC_017730.1 Cp31 2088 1663 441
NC_017945.1 Cp258 2106 1661 503
NC_016932.1 Cp316 2057 1696 502
NC_017307.1 CpCIP52.97 2057 1704 489
NC_018019.1 Cp162 2002 1652 444
NC_017031.1 CpP54B96 2084 1808 543
NC_017462.1 Cp267 2148 1826 561
NC_017306.1 Cp42/02-A 2097 1783 544
NC_017301.1 CpC231 2051 1821 552
NC_017303.1 CpI19 2095 1826 552
NC_016781.1 Cp3/99-5 2099 1759 530
NC_017305.1 CpPAT10 2142 1814 542
NC_014329.1 CpFRC41 2089 1827 559
Table 2. Summary of druggability for all
C. pseudotuberculosis strains, Global highly druggable
(GD) ORFs and Virulent highly druggable (VD) ORFs
NCBI
accession
C. pseudotuberculosis Strain ND or
PD
D HD
NC_017300.1 Cp1002 20 185 377
NC_017308.1 Cp1/06-A 42 224 227
NC_017730.1 Cp31 36 202 203
NC_017945.1 Cp258 39 226 238
NC_016932.1 Cp316 44 232 226
NC_017307.1 CpCIP52.97 39 227 223
NC_018019.1 Cp162 32 196 216
NC_017031.1 CpP54B96 43 241 259
NC_017462.1 Cp267 44 255 262
NC_017306.1 Cp42/02-A 45 249 250
NC_017301.1 CpC231 48 248 256
NC_017303.1 CpI19 44 251 257
NC_016781.1 Cp3/99-5 44 246 240
NC_017305.1 CpPAT10 42 246 254
NC_014329.1 CpFRC41 46 251 262
Global highly druggable (GD)
ORFs
58
Virulent highly druggable (VD)
ORFs
2
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pipeline used in this study. All this work is expandable
and could be applied to the emergence of new strains of
the same organism species as well as to the new organ-
isms with the same characteristics.
Additional material
Additional file 1: Supplementary tables.
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